pegcetacoplan: Clinical Trials

8 trials of pegcetacoplan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 8 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 4, Terminated 2, Not yet recruiting 1, Recruiting 1
Phase 22Recruiting 1, Terminated 1

Follow pegcetacoplan: new trials by email Literature Review of pegcetacoplan trials Research Report on pegcetacoplan

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safely Quenching Complement in Stroke Survivors
Pegcetacoplan Injection [Empaveli] - Acute Ischemic Stroke, Cerebral Infarction
Phase 1Not yet recruitingColumbia University202026-10-012026-04-29
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Phase 1 / Phase 2RecruitingRoswell Park Cancer Institute352026-02-162026-08-19
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RO7669330, Syfovre™, Izervay™ - Geographic Atrophy, Age-related Macular Degeneration
Phase 1TerminatedHoffmann-La Roche272025-07-162026-11-04
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
PEGCETACOPLAN (APL-2) - Geographic Atrophy
Phase 1CompletedApellis Pharmaceuticals, Inc.192018-11-052021-11-10
Pegcetacoplan (APL-2) in Neovascular AMD
Pegcetacoplan - Neovascular Age-related Macular Degeneration
Phase 1 / Phase 2TerminatedApellis Pharmaceuticals, Inc.172018-02-142020-09-16
Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria
Phase 1CompletedApellis Pharmaceuticals, Inc.232015-12-012021-01-11
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1CompletedApellis Pharmaceuticals, Inc.92015-02-232021-01-08
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Pegcetacoplan - Neovascular Age-Related Macular Degeneration
Phase 1CompletedApellis Pharmaceuticals, Inc.132015-01-282020-10-06

Conditions studied

Anemia (2)  ·  Geographic Atrophy (2)  ·  Hematologic Diseases (2)  ·  Hemoglobinuria (2)  ·  Hemoglobinuria, Paroxysmal (2)  ·  Hemolysis (2)  ·  Cerebral Infarction (1)  ·  Ischemic Stroke (1)  ·  Macular Degeneration (1)  ·  Pancreatic Neoplasms (1)  ·  Reperfusion Injury (1)  ·  Thromboinflammation (1)

Sponsors

Apellis Pharmaceuticals, Inc. (5)  ·  Columbia University (1)  ·  Hoffmann-La Roche (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (6)  ·  Australia (1)  ·  Hong Kong (1)  ·  Malaysia (1)  ·  New Zealand (1)  ·  Thailand (1)

Top investigators

Federico Grossi, MD, PhD (3)  ·  Christos Fountzilas (1)  ·  E Sander Connolly, MD (1)  ·  Federico Grossi, MD PhD (1)

Results publications

PMID 35869170, PMID 39079163, PMID 40280279